Psoriatic Arthritis

Psoriatic Arthritis Treatment Trends Investigated

By August 15, 2017

Researchers used claims data between 2004-2015 from a large commercial database to identify patients with psoriatic arthritis who were initiated on DMARDs.

FDA Panel Recommends Approval of Tofacitinib for Psoriatic Arthritis

By August 04, 2017

The supplemental New Drug Applications (sNDAs) contained data from Phase 3 trials involving patients with psoriatic arthritis, including safety analyses from the larger tofacitinib clinical development program.

Ixekizumab Beneficial in Psoriatic Arthritis Refractory to TNFi

May 31, 2017

Two-week and four-week ixekizumab dosing regimens improved signs and symptoms

Patient Develops Psoriatic Arthritis After Multiple Wasp Stings

By December 14, 2016

While rare, cases of arthritis associated with bee and wasp stings have been previously reported in the medical literature.

Tofacitinib Effective in PsA Patients With Prior Inadequate Response

By November 16, 2016

Statistically significant improvements were shown 3 months vs. placebo with tofacitinib, in this new study